Corvus Pharmaceuticals Inc (CRVS)
8.94
+0.70
(+8.50%)
USD |
NASDAQ |
Nov 21, 16:00
8.90
-0.04
(-0.45%)
After-Hours: 20:00
Corvus Pharmaceuticals Enterprise Value: 532.81M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 532.81M |
| November 20, 2024 | 487.83M |
| November 19, 2024 | 498.11M |
| November 18, 2024 | 494.25M |
| November 15, 2024 | 484.62M |
| November 14, 2024 | 505.82M |
| November 13, 2024 | 528.31M |
| November 12, 2024 | 516.74M |
| November 11, 2024 | 556.61M |
| November 08, 2024 | 549.73M |
| November 07, 2024 | 509.05M |
| November 06, 2024 | 507.80M |
| November 05, 2024 | 535.96M |
| November 04, 2024 | 522.82M |
| November 01, 2024 | 527.83M |
| October 31, 2024 | 511.56M |
| October 30, 2024 | 509.05M |
| October 29, 2024 | 514.69M |
| October 28, 2024 | 499.04M |
| October 25, 2024 | 478.39M |
| October 24, 2024 | 438.96M |
| October 23, 2024 | 431.45M |
| October 22, 2024 | 443.34M |
| October 21, 2024 | 431.45M |
| October 18, 2024 | 409.55M |
| Date | Value |
|---|---|
| October 17, 2024 | 409.55M |
| October 16, 2024 | 418.31M |
| October 15, 2024 | 378.89M |
| October 14, 2024 | 383.27M |
| October 11, 2024 | 354.48M |
| October 10, 2024 | 321.94M |
| October 09, 2024 | 333.20M |
| October 08, 2024 | 330.07M |
| October 07, 2024 | 306.29M |
| October 04, 2024 | 311.30M |
| October 03, 2024 | 287.52M |
| October 02, 2024 | 288.77M |
| October 01, 2024 | 276.88M |
| September 30, 2024 | 288.77M |
| September 27, 2024 | 274.89M |
| September 26, 2024 | 271.14M |
| September 25, 2024 | 278.02M |
| September 24, 2024 | 276.77M |
| September 23, 2024 | 293.03M |
| September 20, 2024 | 322.43M |
| September 19, 2024 | 303.67M |
| September 18, 2024 | 295.54M |
| September 17, 2024 | 296.79M |
| September 16, 2024 | 314.30M |
| September 13, 2024 | 271.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-26.95M
Minimum
Mar 16 2020
556.61M
Maximum
Nov 11 2024
60.54M
Average
43.32M
Median
Enterprise Value Benchmarks
| Azenta Inc | 1.613B |
| Perspective Therapeutics Inc | -63.40M |
| Atara Biotherapeutics Inc | -6.078M |
| Clearside Biomedical Inc | 53.77M |
| Quanterix Corp | 152.95M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.22M |
| Total Expenses (Quarterly) | 7.255M |
| EPS Diluted (Quarterly) | -0.60 |
| Earnings Yield | -10.29% |